BioAngels

#BioAngelsBiotechDigest The biotech landscape has been buzzing with activity all week! In the weekly BioAngels Biotech Digest, we spotlight key narratives from the ecosystem: ✅The clinical trial management system market is projected to grow at 14.54% CAGR (2023–2033): https://lnkd.in/dkvKVapT ✅ India joins Bristol Myers Squibb's global drug development efforts: Samit Hirawat (he/him): https://lnkd.in/dcwxGVnb ✅ MicrobioTx unveils finger-prick test to assess gut microbiome health: https://lnkd.in/dbh9Sy2P ✅ Thai research endorses stool DNA as a screening method for non-invasive colorectal cancer: https://lnkd.in/dxVHm-cm ✅ Popular weight-loss drug shows potential in easing arthritis pain: https://lnkd.in/dFdNtjMW ✅ Experimental snakebite pill shows positive early results in Kolkata hospitals: https://lnkd.in/dVZwKqac ✅ 中外製薬 / Chugai Pharmaceutical Co., Ltd. has high hopes for oral obesity treatment trials: https://lnkd.in/dGddG25s ✅ AstraZeneca’s new obesity drug proves safe and tolerable in early trials: https://lnkd.in/dZDAVraf #BioAngelsDigest #BiotechNews #BiotechInnovation #BiotechEcosystem #BiotechTrends #BiotechStartups #InnovationInBiotech #WeeklyBiotechRoundup

Could RNA editing be a game changer for gene therapy? Biotech companies worldwide are showing keen interest in this emerging technology. RNA editing offers a safer and more flexible alternative to DNA editing, allowing for temporary changes rather than permanent alterations to the genome. That way if issues arise during treatment, the therapy can be halted, reducing long-term risk. Whereas DNA-editing tools use proteins from bacteria that may trigger immune reactions, RNA editing relies on ADAR enzymes that occur naturally in the body, making it better suited for people with immune sensitivities. Advances in site-specific RNA editing are drawing interest from scientists today, as they could lead to groundbreaking treatments for a wide range of genetic disorders. Read more: https://lnkd.in/dP-Zrk_n #DNAEditing #RNAEditing #GeneTherapy #Biotech

In the age of transformative biotechnology, biofoundries are emerging as game-changers for India’s life sciences ecosystem. These advanced facilities integrate automation, high-throughput experimentation, and data analytics to accelerate the design and production of biological systems. Bio-innovation and bio-manufacturing are the two key drivers promoting India’s bioeconomy, and biofoundries offer access to both. This creates unique opportunities for emerging startups to use innovative resources, streamline development processes, and reduce costs, positioning them for growth and global competitiveness. BioAngels believes a network of biofoundries across India could foster innovation at an unprecedented scale, enabling startups to push boundaries in fields like synthetic biology, pharmaceuticals, and environmental biotechnology. Such a network would not only enhance resource-sharing and collaboration but also strengthen India’s value creation pipeline in biosciences, ultimately driving impactful solutions to pressing health and environmental challenges. Read more: https://lnkd.in/daxRGtAw #BioAngels #Biofoundries #BiotechInnovation #LifeSciences #SupportingStartups

India’s biotech sector is making remarkable strides in addressing rare genetic disorders. From improved diagnostics to accessible, targeted therapies, recent advancements offer hope for patients suffering from rare conditions with limited treatment options. While there is more work to be done, India’s ongoing biotechnological developments are moving the needle on personalised healthcare and early detection, opening new doors for treatment and improvements in the quality of life. #BioAngels #Biotechnology #RareDiseases #InnovationInHealthcare

Sepsis in newborns, or neonatal sepsis, is a serious medical condition that occurs when a baby younger than 28 days old has a life-threatening response to an infection. Neonatal sepsis affects around 1.3 million births globally with an estimated 200,000 deaths each year. However, there is a silver lining. A genetic signature in newborns can now be used to predict neonatal sepsis before any symptoms start to show. By identifying biomarkers in high-risk newborns, this innovation allows for early intervention, with the potential to save countless lives from a condition responsible for significant neonatal mortality. “Knowing that a newborn child will likely acquire neonatal sepsis would allow doctors to assign precious medical resources to prevent the severe consequences of this disease. Identifying our gene expression signature in the blood will provide that information to physicians,” said Dr Bob Hancock, Professor of Microbiology and Immunology, and Investigator, Centre for Blood Research, University of British Columbia. Since neonatal sepsis is a major health concern in India, this proactive approach holds promise for the country’s healthcare system and aligns with our commitment to advancing critical health innovations. Read more: https://lnkd.in/dVe-bYME #BioAngels #HealthcareInnovation #NeonatalCare #SepsisDetection

India's medtech and pharmaceutical industry, currently valued at US $70 billion, is set to double in size by 2030, solidifying its position as a global healthcare leader. Driven by a robust focus on innovation, indigenous manufacturing, and supportive government policies, this growth will be instrumental in enhancing healthcare access and affordability for millions. Shri Arunish Chawla, Secretary, Department of Pharmaceuticals, noted, “The Contract Research Development Manufacturing Organisation (CRDMO) industry in our country is now growing at 12-14%. For the first time in the closing year, we reached a trade balance between imports and exports as far as bulk drugs are concerned.” India is set to emerge as a major global supplier, meeting both domestic demand and international needs with advancements across diagnostics, therapeutics, and new-age medical devices. As an ecosystem partner dedicated to empowering healthcare startups, BioAngels is delighted to witness this transformative journey that will elevate India’s healthcare sector and address critical health challenges on a worldwide scale. Read more: https://lnkd.in/djprgtWH #BioAngels #Healthcare #Biotech #Innovation #PharmaceuticalIndustry #Medtech

The Indian Council of Medical Research (ICMR) has launched an inspiring new initiative, the “First in the World Challenge”, aimed at empowering Indian scientists to pioneer solutions to the world’s most complex health issues. As one of the oldest and most esteemed biomedical research bodies globally, ICMR seeks to nurture bold, futuristic ideas that generate new knowledge and encourage breakthrough health technologies. Considering that the initiative is high-risk, the launch announcement stated, “ICMR considers it worth taking the risk to achieve something which no one in the world has ever done before. This programme believes in taking big chances for big rewards. Every attempt may not work out, but the successes will bring about a huge revolution in biomedical science.” The “First in the World Challenge” programme will support the discovery and development of visionary solutions, such as vaccines, drugs, diagnostics, and novel interventions, which are yet to be explored or tested globally. BioAngels applauds this remarkable step by ICMR in setting new benchmarks for biomedical innovation. We look forward to witnessing Indian scientists' ingenuity and contributions that will reshape healthcare on a global scale. Read more: https://lnkd.in/dxTdxSsQ #ICMR #FirstInTheWorldChallenge #HealthInnovation #BiomedicalResearch #IndiaInHealthcare #BioAngels #HealthcareTransformation

Lung cancer is the leading cause of cancer-related deaths in India, with smoking, pollution, and occupational hazards contributing to its high incidence. The number of people suffering from lung cancer globally has increased from 6.6 per 1 million in 1990 to 7.7 per 1 million in 2019; the figure is expected to rise significantly in urban areas by 2025. Despite its prevalence, early detection and personalised treatments remain limited, impacting survival and recovery rates significantly. At BioAngels, we are dedicated to supporting startups that are developing advanced screening tools and targeted therapies for lung cancer. If you're a visionary focused on reshaping lung cancer care, we’re here to collaborate with you! Connect with us at www.bioangels.vc/contact/ #LungCancerAwareness #InnovationInCancerCare #BioAngels #HealthcareInnovation #LungCancerCare

Early diagnosis of pancreatic cancer continues to be a challenge today, as the disease often progresses without noticeable symptoms. About one in 56 men and one in 60 women suffer from pancreatic cancer globally, and it is among the leading causes of cancer-related deaths, with survival rates remaining critically low due to late diagnosis. Early detection and innovative therapies are essential to improve outcomes and quality of life for those affected. At BioAngels, we support startups that are working to advance early diagnostics and treatment solutions for pancreatic cancer. If you’re an innovator who is passionate about transforming pancreatic cancer care, let’s make a difference together! Reach out to us at www.bioangels.vc/contact/ #PancreaticCancerAwareness #CancerInnovation #BioAngels #HealthcareAdvancement #CancerCare